[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"blood-pressure-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:blood-pressure-disorders":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,47,74,104,165,200,234],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100364556","early-phase-1-uric-acid-klotho-and-salt-sensitivity-in-young-adults-born-preterm-100364556",false,"NCT04026776","Uric Acid, Klotho and Salt Sensitivity in Young Adults Born Preterm","PEPC3","Inclusion Criteria:\n\n* Singleton birth\n* Born at less than 34 weeks gestational age (preterm cohort)\n* Born at greater than 36 weeks gestational age (term cohort)\n\nExclusion Criteria:\n\n* Twin birth\n* Congenital anomalies or genetic syndromes\n* Currently pregnant or breast feeding\n* Subject-reported history of hypertension\n* Current use of antihypertensive medications\n* Active cancer\n* Chronic kidney disease\n* Heart failure\n* Liver failure",true,"ALL","22 Years","33 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"EARLY_PHASE1","The purpose of this research is to learn about how salt in the diet influences blood pressure in young adults who were born prematurely.",[28,29],"Salt; Excess","Blood Pressure Disorders",[31,32,33],"Uric Acid sensitivity","Salt sensitivity","Blood Pressure Influences","RECRUITING","2026-06-26",{"date":37,"type":38},"2026-06-29","ACTUAL",{"date":40,"type":38},"2020-09-02",{"date":42,"type":22},"2026-12",{"name":44,"class":45},"Wake Forest University Health Sciences","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100604267","arc-im-system-to-manage-symptomatic-blood-pressure-instability-secondary-to-chronic-spinal-cord-injury-100604267","NCT07147296","ARC-IM System to Manage Symptomatic Blood Pressure Instability Secondary to Chronic Spinal Cord Injury","Empower BP","Inclusion Criteria:\n\n1. Aged 18 years or above, and no older than 75 years at the time of enrollment.\n2. Clinical evidence of Orthostatic Hypotension (blood pressure drop of 20mmHg systolic or 10mmHg diastolic) measured during Head Up Tilt Table assessment (HUTT, within 10 minutes) with current standard of care if any. 2 out of 3 tests must meet OH criteria.\n3. Clinical evidence of sustained hypotension (average systolic Blood pressure ≤ 110 mmHg) when measured each minute for 10 minutes while seated and in the absence of supportive compressive garments and medication.\n4. Evidence of symptomatic hypotension as determined by a non-zero OHSA total score\n5. A Spinal cord injury at the neurologic level between C2 and T6 inclusive.\n6. American Spinal Injury Association (ASIA) Impairment Scale (AIS) classification A, B, C, or D.\n7. Traumatic (non-progressive) chronic spinal cord injury with minimum 12 months post-injury prior to study entry.\n8. Average A-P diameter of the sponal canal ≥ 13 mm, measured on MRI at the disc space at level(s) planned for implantation\n9. Stable medical, physical, and psychological condition as considered by the investigators.\n10. Stable dose of blood pressure medication for 30-days prior to enrollment into the study . Stability will be defined as no changes to medication regimens based on treating physician instructions.\n11. Subjects who are on long-term antihypertensive treatment must discontinue these medications no less than 30 days prior to enrollment in the study. This requirement does not apply to antihypertensive agents administered for the acute management of autonomic dysreflexia (AD)\n12. If the subject requires daily continuous support from a personal caregiver, the presence of a caregiver during the study visits is mandatory.\n13. Willing and able to provide informed consent.\n14. Stated willingness to comply with all study procedures and availability for the duration of the study.\n15. Willing and able to comply with the instructions for use, operate the study devices, and comply with this clinical investigation plan\n\nExclusion Criteria:\n\n1. Subject has an autoimmune etiology of spinal cord dysfunction\u002Finjury.\n2. Subject has diseases and conditions that would increase the morbidity and mortality of the surgical procedures required by the study.\n3. Subject has a history of physiologic hypotension prior to SCI\n4. Subject has a history of unexpected blood pressure instability related to medications\n5. Inability to withhold antiplatelet\u002Fanticoagulation agents perioperatively.\n6. History of myocardial infarction or cerebrovascular event within the past 6 months. or\n7. History of chronic\u002Frecurrent severe cardiac arrythmias (e.g., ventricular tachycardia, ventricular fibrillation, third degree atrioventricular block)\n8. Evidence of clinically significant underlying cardiac conditions on Holter monitoring performed at screening including but not limited to arrhythmias (e.g., atrial fibrillation, ventricular tachycardia),\n9. Evidence of ischemic changes or prolonged QT interval (QTc \\> of 450 ms for males and 470 ms for females) identified on EKG during screening,\n10. Subjects with a known diagnosis of heart failure, including but not limited to New York Heart Association (NYHA) Class I-IV, or with evidence of clinically significant left ventricular dysfunction (ejection fraction \\\u003C 40%) as determined by echocardiogram during screening or within the past 6 months,\n11. Current renal\u002Fkidney, hepatic, or other concomitant disorders deemed severe by the Investigator including those ones that could be linked to severe autonomic dysreflexia.\n12. Requires continuous ventilator support.\n13. Imaging (MRI, CT, X-ray) findings within the last 12 months that contraindicate lead placement\n14. Known allergic reaction to implanted materials\n15. Requires continuous\u002Ffrequent\u002Fany transcutaneous spinal cord stimulation treatment.\n16. Has any active implanted medical device (e.g. baclofen pump, pacemaker).\n17. Inability to receive a pre-operative MRI.\n18. Female subject who is pregnant, breastfeeding or planning to become pregnant or breastfeed. Women of child-bearing potential must have a negative pregnancy test completed at baseline visit per site standard test.\n19. Presence of pressure sore at time of screening or baseline graded stage 3 or 4 .\n20. Subject is enrolled or intends to participate in another clinical drug and\u002For device study or registry that may interfere with the results of this study, as determined by ONWARD Medical personnel.\n21. Presence of other anatomic or comorbid conditions, or other medical, social, or psychologic conditions such as severe uncontrolled neuropathic pain, depression, history of alcohol or substance abuse, history of schizophrenia or psychotic illness, severe personality disorder or other significant psychiatric or cognitive disorders that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements of the clinical investigation.","18 Years","75 Years",{"count":57,"type":22},60,[59],"NA","Empower BP is a pivotal, interventional, multicenter, prospective, randomized, controlled double-blinded study to evaluate the safety and effectiveness of the ARC-IM System in managing symptomatic blood pressure instability in individuals with chronic SCI (\\>1 year after SCI).\n\nThe primary effectiveness outcome will be evaluated through subject-reported ADFSCI and seated blood pressure assessments at 3 months post-implant.\n\nFollowing a baseline screening period and the surgical implantation of the ARC-IM System, subjects will be randomized with a 2:1 ratio into an active or control arm for 3 months. All the subjects will undergo therapy activation sessions (into either Group 1: active intervention, or Group 2: intervention aimed to mimic the active intervention without the active component) within 21 days of the surgical implant and will then commence independent at-home use of ARC-IM Therapy. At the 3 Month timepoint, after all assessments are conducted, all subjects will transition to the open-label period in order to receive the active version of the ARC-IM System in an open-label fashion. All subjects will undergo therapy programming sessions following Month 3.",[62,29],"Spinal Cord Injuries","2026-06-15",{"date":65,"type":38},"2026-06-16",{"date":67,"type":38},"2025-10-17",{"date":69,"type":22},"2029-03",{"name":71,"class":72},"ONWARD Medical, Inc.","INDUSTRY",13,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100560480","smartphone-blood-pressure-measurement-to-screen-for-hypertension-100560480","NCT06577688","Smartphone Blood Pressure Measurement to Screen for Hypertension","Assessing the Feasibility of Classifying People Using a Machine-learning Approached Based on Features Derived From Smartphone Video Data Recorded at the Person's Fingertip","Optiscreen","Inclusion Criteria:\n\n* Informed consent as documented by signature\n* Men or women older than 18 years old\n* Good understanding of written and oral speaking used at the center where the study will be carried out\n\nExclusion Criteria:\n\n* Patients that cannot sign informed consent\n* Patients in emergency situation, are not legally competent, cannot understand the situation or are vulnerable\n* Unable to participate due to pain or stress \\[12\\]\n* Known or suspected non-compliance (e.g. drug or alcohol abuse, language problems, psychological disorders, dementia)\n* Patients older than 80 years old \\[4\\] \\[13\\]\n* Known pregnancy\n* Known unstable cardiac condition (myocardial infarction \\\u003C 1 week, decompensated heart failure, pulmonary embolism)\n* End-stage renal disease (GFR \\\u003C 15\u002Fmin\u002F1.73m2 and\u002For dialysis) \\[4\\] \\[14\\] \\[15\\] \\[16\\]\n* Diabetes mellitus \\[15\\] \\[8\\]\n* Known (or assessed by recording heart rate and using pulse palpation, as recommended in ESC\u002FESH guidelines \\[1\\]) cardiac arrhythmia (atrial fibrillation, numerous extrasystoles and important bradycardia\u002Fbradyarrhythmia, bigeminy, trigeminy, isolated VPB) \\[4\\] \\[1\\] \\[7\\] \\[15\\] \\[17\\]\n* SBP or DBP difference between two arms \\>10 mmHg \\[8\\] \\[18\\]\n* Patient with finger lesions that would alter the correct capture of signals by the mobile phone.\n* Known mobile phone contact dermatitis (caused by metal allergens, notably nickel and chromium\n* Incapacity of properly using the smartphone (i.e. incapacity of obtaining a recording with sufficient signal quality after the dedicated training)","80 Years",{"count":84,"type":22},100,"OBSERVATIONAL","The goal of this observational study is to assess the feasibility of classifying people whose blood pressures are within hypertensive range using a machine-learning approach based on features derived from smartphone video data recorded at the patient's fingertips. The main question\\[s\\] it aims to answer are:\n\nIs a smartphone a reliable device for high blood pressure screening ? Is a smartphone a reliable device for blood pressure monitoring ? Participants will record their blood pressure with a smartphone at their fingertips and with an approved cuff device, 3 times in the morning and 3 times in the evening for 7 days. There will be two groups, a volunteer presumed healthy, and a volunteer addressed for a Home Blood pressure monitoring with the diagnosis of hypertension suspected.\n\nResearchers will compare the two groups to see if the smartphone can be reliable in terms of diagnosis and monitoring of the blood pressure comparing to a standard cuff device.",[88,29],"Blood Pressure",[90,91,92,93],"blood pressure","smartphone","Home blood pressure monitoring","Blood pressure disorders screening","2026-03-24",{"date":96,"type":38},"2026-03-27",{"date":98,"type":38},"2024-09-01",{"date":100,"type":22},"2026-12-30",{"name":102,"class":45},"Centre Hospitalier Universitaire Vaudois",2,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":16,"sex":17,"minAge":112,"maxAge":54,"enrollmentInfo":113,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":115,"conditions":116,"keywords":134,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":164,"locationsCount":46},"100420250","pediatric-hypertension-and-the-renin-angiotensin-system-phrase-100420250","NCT04752293","Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)","Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage","PHRASE","INCLUSION CRITERIA: HYPERTENSION COHORT\n\n* 7-18 years of age at time of enrollment\n* Confirmed new diagnosis of primary hypertension: no identifiable secondary cause, referred to hypertension or nephrology clinic\n\n  * Age \\\u003C13 years: BP ≥95th %ile or ≥130\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP ≥130\u002F80 mmHg\n* Participants and their caregivers must be willing and able to commit to completing the study assessments\n\nEXCLUSION CRITERIA: HYPERTENSION COHORT\n\n* \\\u003C7 years or \\>18 years of age at time of enrollment\n* BP confirmed as normal or in the elevated BP category based on ≥3 prior office BP measurements on separate days;\n\n  * Age \\\u003C13 years: BP \\\u003C95th %ile or \\\u003C130\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP \\\u003C130\u002F80 mmHg\n* A confirmed secondary cause of hypertension\n* Confounding medical condition (heart or kidney disease \\[except hypertension-associated heart changes on echocardiogram or albuminuria\\], vascular\u002Finflammatory disease, or diabetes)\n* Inability to complete study assessments\n* Non-English\u002FSpanish speakers\n* Current pregnancy\n* Ward of the State\n\nINCLUSION CRITERIA: CONTROL COHORT\n\n* 7-18 years of age at time of enrollment\n* Normal BP based on ≥3 prior office BP measurements on separate days;\n\n  * Age \\\u003C13 years: BP \\\u003C90th %ile or \\\u003C120\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP \\\u003C120\u002F80 mmHg\n* Participants and their caregivers must be willing and able to commit to completing the study assessments\n\nEXCLUSION CRITERIA: CONTROL COHORT\n\n* \\\u003C7 or \\>18 years of age at time of enrollment\n* Elevated BP or hypertension, based on ≥3 prior office BP measurements on separate days:\n\n  * Age \\\u003C13 years: BP ≥90th %ile or ≥120\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP ≥120\u002F80 mmHg\n* History of elevated BP or hypertension\n* Current use of BP-lowering medications\n* Confounding medical condition (heart or kidney disease, vascular\u002Finflammatory disease, or diabetes)\n* Inability to complete study assessments\n* Non-English\u002FSpanish speakers\n* Current pregnancy\n* Ward of the State","7 Years",{"count":114,"type":22},125,"Studying the causal roles of components of the renin-angiotensin-aldosterone system (including angiotensin-(1-7) (Ang-(1-7)), angiotensin-converting enzyme 2 (ACE2), Ang II, and ACE), uric acid, and klotho in pediatric hypertension and related target organ injury, including in the heart, kidneys, vasculature, and brain. Recruiting children with a new hypertension diagnosis over a 2-year period from the Hypertension and Pediatric Nephrology Clinics affiliated with Brenner Children's Hospital at Atrium Health Wake Forest Baptist and Atrium Health Levine Children's Hospital. Healthy control participants will be recruited from local general primary care practices. Collecting blood and urine samples to analyze components of the renin-angiotensin-aldosterone system (Ang-(1-7), ACE2, Ang II, ACE), uric acid, and klotho, and measuring blood pressure, heart structure and function, autonomic function, vascular function, and kidney function at baseline, year 1, and year 2. Objectives are to investigate phenotypic and treatment response variability and to causally infer if Ang-(1-7), ACE2, Ang II, ACE, uric acid, and klotho contribute to target organ injury due to hypertension.",[117,118,119,120,121,122,123,124,125,29,126,127,128,129,130,131,132,133],"Hypertension","Left Ventricular Hypertrophy","Left Ventricular Dysfunction","Left Atrial Dilatation","Left Ventricular Diastolic Dysfunction","Kidney Diseases","Kidney Injury","Kidney Dysfunction","Sodium Urine High","Uric Acid Retention","Angiotensin Hypertension","Autonomic Dysfunction","Autonomic Imbalance","Pediatric Kidney Disease","Pediatric Obesity","Proteinuria","Albuminuria",[135,136,117,137,138,118,133,139,140,141,142,143,144,145,146,147,148,149,150,151,121,123,152,153,131,154,155,156,157],"High Blood Pressure","Elevated Blood Pressure","Pediatric Hypertension","Target Organ Damage","Uric Acid","Klotho","Fibroblast Growth Factor 23","Renin-Angiotensin-Aldosterone System","Renin-Angiotensin System","Angiotensin-(1-7)","Angiotensin II","Angiotensin-Converting Enzyme 2","Angiotensin-Converting Enzyme","Causal Inference","Causal Mediation Analysis","Sensitivity Analysis","Predictive Analysis","Heart Rate Variability","Sodium","Lifecourse","Kidney Function","Ambulatory Blood Pressure Monitoring","Echocardiogram","2025-12-04",{"date":160,"type":38},"2025-12-11",{"date":162,"type":38},"2021-05-19",{"date":42,"type":22},{"name":44,"class":45},{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":173,"targetDuration":175,"studyType":85,"phases":4,"briefSummary":176,"conditions":177,"keywords":186,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":46},"100571925","interprofessional-pharmacogenomics-ipgx-registry-and-repository-100571925","NCT06726590","Interprofessional Pharmacogenomics (IPGx) Registry and Repository","The Texas Interprofessional Pharmacogenomics Registry and Repository","IPGx Registry","Inclusion Criteria:\n\n* The study will invite patients who are eligible for PGX workup\u002FPGX care to participate, provided they meet the following criteria: Use of five or more medications, including over the counter drugs, supplements, natural products, cannabis products, or other recreational drugs, or\n* Individuals taking blood pressure or depression medications, even if less than five medications.\n* Ability to understand and give consent.\n* Able to consent to donate blood and\u002For urine samples and buccal swabs.\n* Able to answer detailed questionnaires, including quarterly questionnaires about ADRs, cognitive testing such as serial mini-mental status exams, and or quality of life questions.\n* Able to understand that their health record and changes in health status will be followed for a five-year period and shared in deidentified form with the research community.\n* All genders.\n* Any age over 18 years.\n\nExclusion Criteria:\n\n* Individuals admitted to hospice.\n* Declines to participate or interact with staff\u002Fshare their medical status.\n* A diagnosis of Alzheimer's disease or related dementias in a medical record as this indicates a progressive, debilitating condition that impairs memory, thought processes, and functioning.,\n* Individuals who are unable or unwilling to provide consent.\n* Unable to verbally communicate and comprehend English language",{"count":174,"type":22},3000,"6 Months","This program collects genetic and health information to help doctors choose the right medications for patients.",[178,179,180,29,181,182,183,184,185],"Diabetes","Cholesterol","Cancer","Heart Disease","Respiratory Ilness","COPD","Adverse Drug Reaction (ADR)","Poly Pharmacy",[187,188,189,190],"REGISTRY","REPOSITORY","POLYPHARMACY","ADVERSE DRUG REACTION","2025-09-05",{"date":193,"type":38},"2025-09-12",{"date":195,"type":22},"2025-11",{"date":197,"type":22},"2029-11",{"name":199,"class":45},"Texas A&M University",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":23,"phases":211,"briefSummary":212,"conditions":213,"keywords":219,"overallStatus":224,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":46},"100558748","exploring-physical-exercise-for-the-regulation-and-control-of-metabolic-disorders-in-college-students-100558748","NCT06555159","Exploring Physical Exercise for the Regulation and Control of Metabolic Disorders in College Students.","EFFECT OF AN AEROBIC EXERCISE PROGRAM ON METABOLIC DISORDERS LEVELS IN HIGHER EDUCATION STUDENTS AT THE UNIVERSITY OF COLIMA, RANDOMIZED CLINICAL TRIAL.","(EPE_RCTMCS)","Inclusion Criteria:\n\n* University of Colima students linked to the central campus.\n* Students aged between 18 and 25 years old.\n* Authorization to participate in the project with a signed informed consent.\n* Suffer from at least one of the parameters of metabolic disorders or cardiovascular risk (Hyperglycemia, decreased DHL, elevated triglycerides, abdominal obesity or hypertension) following the clinical assessment (Considering the criteria established by the ADA and ATPIII).\n\nExclusion Criteria:\n\n* Motor limitations that may hinder the performance of physical exercise.\n* Pregnancy or lactation.\n* High Vigorous Physical Activity Level according to the IPA-Q.\n* To be currently under pharmacological treatment to manage altered metabolic levels.\n\nELIMINATION CRITERIA\n\n* Musculoskeletal injuries during the study period.\n* Unforeseen Medical Events: Unexpected medical situations that could influence study results, such as hospitalizations, serious illnesses, or surgeries.\n* Non-Compliance with Follow-Up: Subjects failing to meet a minimum of 80% (19 out of 24 sessions) of the stipulated physical conditioning program time.\n* Initiation of clinical treatment that may affect protocol results, such as medications that reduce alterations.\n* Participants who voluntarily withdraw from the study.","25 Years",{"count":210,"type":22},48,[59],"This clinical trial objective is to evaluate the effect of an aerobic physical exercise program on reducing triglycerides, blood pressure, abdominal obesity, altered glucose levels, and the increase in HDL in college-level students at the University of Colima. It will try to answer whether aerobic physical exercise reduces metabolic disorders (altered blood pressure and glucose levels, abdominal obesity, and increased HDL). A simple randomized clinical trial will be conducted with a sample of 48 voluntary students from the University of Colima, divided into two groups of 24 people (Control group -A-, will perform aerobic physical exercise, which will be walking at 57% to 76% of HRmax; and Experimental Group -B-, will undergo an aerobic physical exercise (APE) program involving jogging, swimming, and static cycling, with a progressive intensity, which will start at 57%-63% of the maximum heart rate (HRmax) in the first 4 weeks of the study, and will increase to 64% -76% in the final four weeks, fulfilling the principle of progressive overload).\n\nResearchers will compare the results of both groups to confirm the effectiveness of the planned aerobic physical exercise in reducing these risks.",[214,215,29,216,217,218],"Metabolic Disorders","Abdominal Obesity","Hypertriglyceridemia","Hyperglycemia","HDL-Deficiency",[220,221,222,223,117],"Exercise","Obesity","HDL","Triglycerides","NOT_YET_RECRUITING","2024-08-12",{"date":227,"type":38},"2024-08-15",{"date":229,"type":22},"2024-09",{"date":231,"type":22},"2025-06",{"name":233,"class":45},"Universidad de Colima",{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":17,"minAge":241,"maxAge":242,"enrollmentInfo":243,"targetDuration":4,"studyType":23,"phases":245,"briefSummary":246,"conditions":247,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":46},"100516136","safety-feasibility-and-efficacy-of-tscs-on-stabilizing-blood-pressure-for-acute-inpatients-with-sci-100516136","NCT06000592","Safety, Feasibility, and Efficacy of TSCS on Stabilizing Blood Pressure for Acute Inpatients With SCI","Safety, Feasibility, and Efficacy of Transcutaneous Spinal Cord Stimulation on Stabilizing Blood Pressure for Acute Inpatients With Spinal Cord Injury","Inclusion Criteria:\n\n* Newly injured patients with traumatic SCI\n* Admitted to Acute Inpatient Rehabilitation at Mount Sinai\n* Within one year of SCI\n* Seated hypotension (systolic BP ≤ 110 mmHg for males or ≤ 100 mmHg for females)\n* Orthostatic hypotension (fall in systolic BP ≥ 20 mmHg and\u002For a fall in diastolic BP ≥ 10 mmHg within 10 minutes of assuming an upright position)\n* Daily fluctuation in systolic BP ≥ 20 mmHg and\u002For fluctuation in diastolic BP ≥ 10 mmHg\n* At least 14 years old\n\nExclusion Criteria:\n\n* Implanted brain\u002Fspine\u002Fnerve stimulators\n* Cochlear implants\n* Cardiac pacemaker\u002Fdefibrillator, or intracardiac lines\n* Open skin lesions on or near the electrode placement sites (neck, upper back)\n* Significant coronary artery or cardiac conduction disease\n* Recent history of myocardial infarction\n* Insufficient mental capacity to understand and independently provide consent\n* Pregnancy\n* Cancer\n* Deemed unsuitable by study physician","14 Years","100 Years",{"count":244,"type":22},50,[59],"Current forms of pharmacologic and non-pharmacologic treatments for hypotension and orthostatic hypotension (OH) remain inadequate during acute inpatient rehabilitation (AIR) following a traumatic spinal cord injury (SCI). A critical need exists for the identification of safe, practical, and effective treatment options that stabilize blood pressure (BP) after traumatic SCI. Recent published evidence suggests that transcutaneous Spinal Cord Stimulation (TSCS) can be used to raise seated BP, and mitigate the falls in BP during orthostatic repositioning in individuals with chronic SCI. This site-specific project will focus on the use of TSCS to stabilizing seated BP and mitigate the fall in BP during orthostatic repositioning during AIR following traumatic SCI.",[248,62,249,250,251,252,88,29],"Acute Spinal Cord Injury","Neuromodulation","Traumatic Spinal Cord Injury","Spinal Cord Stimulation","SCI - Spinal Cord Injury","2024-04-01",{"date":255,"type":38},"2024-04-02",{"date":257,"type":38},"2022-01-01",{"date":259,"type":22},"2026-10-01",{"name":261,"class":262},"Jill M. Wecht, Ed.D.","FED"]